GlobalData’s report suggests that the leading driver of this reasonably robust growth will be the anticipated launches of five biologics for the treatment of various forms of vasculitis, including Bristol-Myers Squibb’s (BMS) Orencia, Johnson & Johnson’s Remicade, GlaxoSmithKline’s (GSK) Benlysta and Nucala, and Roche’s Actemra.
Vasculitis is a condition that involves inflammation in the blood vessels and the condition occurs if your immune system attacks your blood vessels by mistake.
There are many types of vasculitis but overall the condition is rare, however GlobalData believes the improved effectiveness and lack of inconvenient side effects that come with the introduction of new MOAs offer "exciting prospects for drug companies".
GlobalData analyst Alexandra Annis MS said: "The regulatory approval of these drugs throughout the forecast period will introduce four novel mechanisms of action (MOAs) to the market, which will address current unmet needs well.
"The greatest unmet needs in the vasculitis market are improved safety and efficacy for both induction and maintenance therapies, as induction regimens for the management of vasculitis typically come with a considerable list of side effects."
Financially the projected growth is from under $342 million in 2014 to over $558 million by 2024, at a Compound Annual Growth Rate (CAGR) of 5.1%.
The analyst added that Roche’s Actemra, BMS’s Orencia and GSK’s Nucala are anticipated to be the most successful of the new vasculitis treatment market entrants, as they have demonstrated strong efficacy and safety in clinical trials.
Read the full forecast at http://store.globaldata.com/market-reports/pharmaceuticals-and-healthcare/opportunityanalyzer-vasculitis-opportunity-analysis-and-forecast-to-2024#.Vo5q1_krK70